Results 181 to 190 of about 144,610 (311)

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. [PDF]

PLoS One
Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, Phillips W, Maxfield M, Uy K, Lou F.   +9 more
europepmc   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, EarlyView.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source

The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer. [PDF]

Cancers (Basel)
Wadud S, Cheadle EJ, Sutton PA.
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer. [PDF]

Breast Cancer (Dove Med Press)
Tian C, Qiu J, Fan Y, Yu H, Liu S.
europepmc   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Ultrasound and Clinicopathological Features-Based Machine Learning Model for Predicting Neoadjuvant Therapy Efficacy in Breast Cancer. [PDF]

Cancer Rep (Hoboken)
Hao T, Ji X, Zhao Q, Wei M.
europepmc   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, EarlyView.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source